Whitepaper: Accelerate biologics development via innovation
This whitepaper provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly.
For most pharmaceutical and biotech companies rising to the challenges of biologics development, this means identifying trusted partners who can provide access to innovative technologies and methodologies, sufficient manufacturing capacity, deep expertise in navigating regulatory channels, and the operational efficiencies to accelerate speed to market. This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly.
Related content from this organisation
- Technical note: System precision in HPLC analysis of APIs and impurities
- Event review: The Future of QA/QC for Complex Biologics
- Application note: Achieve complete lab access with extended reality LIMS software
- Application Notes Supplement 2021
- Many hands make light work: why the new Bespoke Gene Therapy Consortium is a godsend for ambitious biopharma teams
Biologics, Biopharmaceuticals, Biosimilars, Drug Delivery Systems, Excipients, Formulation, Freeze Drying, Gene therapy, Good Manufacturing Practice (GMP), Ingredients, Manufacturing, Microbiology, Outsourcing, Packaging, QA/QC, Regulation & Legislation, Research & Development (R&D), Stem Cells, Supply Chain, Vaccines